Technology | Artificial Intelligence | March 19, 2018

Philips Launches HealthSuite Insights AI Platform for Healthcare

Online marketplace offers curated, readily available AI assets for license

Philips Launches HealthSuite Insights AI Platform for Healthcare

March 19, 2018 — Philips recently announced the launch of HealthSuite Insights, including the Insights Marketplace, to support the advancing adoption of analytics and artificial intelligence (AI) in key healthcare domains. Making their debut at the 2018 Healthcare Information and Management Systems Society Conference and Exhibition (HIMSS18), March 5-9 in Las Vegas, HealthSuite Insights gives data scientists, software developers, clinicians and healthcare providers access to advanced analytic capabilities to curate and analyze healthcare data and offers them tools and technologies to build, maintain, deploy and scale AI-based solutions. Insights Marketplace will provide the healthcare industry's first ecosystem where curated AI assets from Philips and others are readily available for license.

AI-based solutions have great potential to improve patient outcomes and care efficiency, according to Philips. However, developing and deploying AI solutions for healthcare use cases can be time consuming, resource intensive and expensive. HealthSuite Insights eases the logistical challenges of deploying AI solutions in research and clinical environments. It accelerates the development of analytics solutions, and reduces development and total cost of AI solutions.

"The quality of your AI is only as good as the quality of the data you feed into it," said Jeroen Tas, Chief Innovation & Strategy Officer Philips. "We have designed HealthSuite Insights to be used by the people who work with patient data on a daily basis and have the contextual understanding; including doctors, clinicians and hospital managers.” He added that the platform gives users the ability to bring all the relevant patient information together, curate the data and use the power of AI to support precision diagnosis, personalized therapy, early intervention and greater hospital efficiency.

The tools and technologies available through HealthSuite Insights already enable the machine learning and deep learning applications in Philips' diagnostic imaging solutions, patient monitoring solutions, and oncology and genomics offerings. Enabled by the platform, Philips leverages AI across these offerings, by combining it with other technologies and a deep understanding of the clinical, operational and personal context to augment care professionals and patients/consumers.

Philips' Insights Marketplace initially offers assets supplied by Philips – including assets developed by scientists at Philips Research. Medically validated Philips assets will be added later this year. In late 2018, the Insights Marketplace will be further expanded to include assets submitted by third parties.

AI assets built using the Insights Platform are designed to be secure regardless of the execution environment, with sophisticated identity and access management, integrated blockchain services, and data collection and management services built in. The Insights platform can be deployed on a healthcare cloud infrastructure such as the Philips HealthSuite Digital Platform, or on premise at a provider site.

For more information: www.usa.philips.com/healthcare

 

Related Content

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
PaxeraHealth enterprise imaging, PACS, VNA solutions
News | Enterprise Imaging | February 11, 2020
February 11, 2020 — Enterprise Imaging developer PaxeraHealth
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019.

An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019. Photo by Dave Fornell.

Feature | Artificial Intelligence | February 07, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...
Sponsored Content | Videos | Artificial Intelligence | February 07, 2020
At RSNA19, GE Healthcare introduced its...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

News | Artificial Intelligence | February 04, 2020
February 4, 2020 — Since January 2020, the...